DNC Peptides

Back to the library

BPC-157

Research draft Repair and healing research Best evidence grade B Human research reviewed, scope limited

Evidence design, not proof of benefit or product approval

Holds on this record

The nine headings

Each heading opens a plain summary, then the deeper evidence and the sources behind it.

What it is

BPC-157 is an experimental peptide. Human findings checked here are small and uncontrolled.

Sources for this tile

The history

Most mechanistic work remains in cells or animals. The human knee report is often overstated by pooling BPC alone with a combination.

Sources for this tile

How it works

Open the pathway notes below. A biological pathway is a possible chain of events in the body. The grade states where it was tested.

Sources for this tile

Each proposed mechanism

Blood-vessel signals

VEGFR2-Akt-eNOS signalling was studied in endothelial cells. Animal models assessed blood supply. It is a proposed pathway, not proof of human tendon repair.

Evidence note: D

Sources

Tendon-cell response

Cultured rat tendon cells showed more growth hormone receptor expression and a response to growth hormone. Cells in a dish are not a healed tendon in a person.

Evidence note: D

Sources

Go deeper

Blood-vessel signals D

VEGFR2-Akt-eNOS signalling was studied in endothelial cells. Animal models assessed blood supply. It is a proposed pathway, not proof of human tendon repair.

Sources

Tendon-cell response D

Cultured rat tendon cells showed more growth hormone receptor expression and a response to growth hormone. Cells in a dish are not a healed tendon in a person.

Sources

What it helps

Open the outcome notes. They show the tested condition and what was measured. A positive marker, a mouse result and a clinical benefit are different things.

Sources for this tile

Read this before you read a benefit into it

Laboratory and animal results describe what happened in that model. They are not proven healing in a person. Human studies name their own population, outcome and limits. Both are kept apart here on purpose.

Human research found for this product

BPC-157: retrospective knee pain reports B
Proof gradeB
DesignRetrospective reports without a control group
People or modelPeople reached after knee treatment; 17 charts initially reviewed
Number16
Outcome measuredSelf-reported knee relief
ResultBPC alone: 11 of 12 reported improvement. BPC with thymosin beta-4: 3 of 4. The pooled 14 of 16 result must not be labelled BPC alone. No standardised function score was used.
Route in the studyIntra-articular
DurationRetrospective follow-up; timing varied
Personal regimenNot set. A study regimen is not a personal instruction.

Source

BPC-157: uncontrolled bladder pain study B
Proof gradeB
DesignUncontrolled case series
People or modelWomen with interstitial cystitis
Number12
Outcome measuredSelf-reported bladder symptoms
ResultTen reported full relief and two partial relief after a local procedure. No control group showed how much was due to the treatment.
Route in the studyLocal bladder procedure
DurationFollow-up study; exact timing not extracted
Risks notedNo adverse events reported in this small series.
Personal regimenNot set. A study regimen is not a personal instruction.

Source

BPC-157: two-person IV safety pilot B
Proof gradeB
DesignUncontrolled short safety pilot
People or modelAdults previously exposed to BPC-157
Number2
Outcome measuredShort-term safety observations
ResultNo adverse effects were reported during the brief pilot. Two people cannot establish long-term safety or healing benefit.
Route in the studyIntravenous
DurationTwo treatment days; blood follow-up on day 3
Risks notedNo reported events; sample too small for rare harms.
Personal regimenNot set. A study regimen is not a personal instruction.

Source

Go deeper

Self-reported knee relief B

B: Tested in People reached after knee treatment; 17 charts initially reviewed. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

Self-reported bladder symptoms B

B: Tested in Women with interstitial cystitis. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

Short-term safety observations B

B: Tested in Adults previously exposed to BPC-157. Read the study result in the human or researcher layer. This is a tested outcome, not a promised benefit.

Sources

The research

Each claim keeps its own source, evidence grade and limits. This is a scoped first research edition. It is not a full review or a personal treatment plan.

Sources for this tile

Overall state of the evidence

Status: scoped-human-evidence

These studies do not prove general gut healing, tendon repair or long-term safety. The FDA notice also flags compounding concerns. Supplier identity, purity and sterile quality are separate from a paper.

Risk summary

These studies do not prove general gut healing, tendon repair or long-term safety. The FDA notice also flags compounding concerns. Supplier identity, purity and sterile quality are separate from a paper.

Unwanted effects reported in the sources

  • No adverse events reported in this small series. (BPC-157: uncontrolled bladder pain study)
  • No reported events; sample too small for rare harms. (BPC-157: two-person IV safety pilot)

What is still open

  • Supplier identity and batch match have not been verified
  • Full-text systematic review and complete interactions are not finished
  • Exact product identity
  • Target condition and other causes of pain
  • Allergies and current medicines
  • Baseline pain and function

Checks a reviewer must finish first

  • Exact product identity
  • Target condition and other causes of pain
  • Allergies and current medicines
  • Baseline pain and function

How to read the proof grades

  • A: Controlled human trial. Note whether randomisation and blinding were confirmed.
  • B: Small uncontrolled human study or chart review.
  • C: Whole-animal intervention.
  • D: Cell or other laboratory study.
  • E: User reports. Kept separate and never substituted for a measured outcome.
  • ungraded: Identity sources, official labels, notices, reviews and unverified claims are not assigned an efficacy grade.

Go deeper

How to read the proof Open the checked detail

A: controlled human trial. State whether it was blinded and randomized. B: small uncontrolled human study or chart review; a weak clinical comparison is marked with its design limits. C: whole-animal work. D: cells or other lab work. E: user reports.

A grade describes the kind of evidence for one claim. It does not grade every claim about a peptide or approve a product. Labels, history and regulatory reviews are named sources, not efficacy grades.

Sources

Open questions Open the checked detail

Supplier identity and batch match have not been verified

Full-text systematic review and complete interactions are not finished

Exact product identity

Target condition and other causes of pain

Allergies and current medicines

Baseline pain and function

Research in people

Open the linked human study records. Each names the tested group, design, result and limits. Related-compound and non-treatment studies are marked so they cannot be used as product treatment proof.

Sources for this tile

Studies named in this tile

Personal regimenNot set. A study regimen is not a personal instruction.
Personal regimenNot set. A study regimen is not a personal instruction.
Personal regimenNot set. A study regimen is not a personal instruction.

What people report

No user reports are recorded for this product. The library keeps human studies and user reports in separate places, so nothing is filled in here.

Each human record

BPC-157: retrospective knee pain reports B
Proof gradeB
DesignRetrospective reports without a control group
People or modelPeople reached after knee treatment; 17 charts initially reviewed
Number16
Outcome measuredSelf-reported knee relief
ResultBPC alone: 11 of 12 reported improvement. BPC with thymosin beta-4: 3 of 4. The pooled 14 of 16 result must not be labelled BPC alone. No standardised function score was used.
Route in the studyIntra-articular
DurationRetrospective follow-up; timing varied
Personal regimenNot set. A study regimen is not a personal instruction.

Source

BPC-157: uncontrolled bladder pain study B
Proof gradeB
DesignUncontrolled case series
People or modelWomen with interstitial cystitis
Number12
Outcome measuredSelf-reported bladder symptoms
ResultTen reported full relief and two partial relief after a local procedure. No control group showed how much was due to the treatment.
Route in the studyLocal bladder procedure
DurationFollow-up study; exact timing not extracted
Risks notedNo adverse events reported in this small series.
Personal regimenNot set. A study regimen is not a personal instruction.

Source

BPC-157: two-person IV safety pilot B
Proof gradeB
DesignUncontrolled short safety pilot
People or modelAdults previously exposed to BPC-157
Number2
Outcome measuredShort-term safety observations
ResultNo adverse effects were reported during the brief pilot. Two people cannot establish long-term safety or healing benefit.
Route in the studyIntravenous
DurationTwo treatment days; blood follow-up on day 3
Risks notedNo reported events; sample too small for rare harms.
Personal regimenNot set. A study regimen is not a personal instruction.

Source

Why it is for you

This is the shared library. No client has been assessed in this record. This tile will use the person's own words, a named target and checked rule-outs after intake. A catalog entry does not mean it is suitable for someone.

Not filled in for you yet

This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.

What you would notice

These studies do not prove general gut healing, tendon repair or long-term safety. The FDA notice also flags compounding concerns. Supplier identity, purity and sterile quality are separate from a paper.

Sources for this tile

Not filled in for you yet

This heading is personal. It stays blank until your own intake is reviewed and a plan is agreed with you. Nobody else's reasons or results are shown here.

How it is taken

Human reports used local joint, bladder and IV routes. They do not validate a general injection schedule under the skin. Research routes describe what was studied. They are not a client administration guide.

Sources for this tile

Routes seen in the research

  • Intra-articular
  • Local bladder procedure
  • Intravenous

Dose and cycle fields in the library

These are blank on purpose. A personal amount, schedule, mixing or storage instruction is only written into an agreed plan after a reviewer checks the exact product.

doseBlank
unitBlank
frequencyBlank
timeOfDayBlank
foodTimingBlank
routeBlank
injectionSiteBlank
cycleLengthBlank
restLengthBlank
titrationBlank
mixingBlank
storageBlank
expiryAfterMixingBlank

Identity

What it is made ofBPC-157 is an experimental peptide. Human findings checked here are small and uncontrolled.
MakerNot recorded
Supplier batch matchedNo. Not matched to a supplier batch.
Catalog sizes5mg to 20mg - Inherited reference only; stock and current product sizes unverified
Record checked on2026-10-08

Shared safety note

FDA flags immune reactions and impurities in several compounded peptides. Its notice also reports serious events in IV ipamorelin research, heart-rate and vessel-dilation reactions with CJC-1295, glucose concerns with GHRP-2/6, and serious case reports with melanotan II. Reports do not by themselves establish causation. This concerns proposed compounded products and routes, not every formulation worldwide.

Source